金陵药业 (000919.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	3.2B	3.2B	3.3B	3.2B	2.7B
Cost of Revenue	2.5B	2.5B	2.7B	2.6B	2.1B
Gross Profit	675.5M	667.0M	605.7M	637.4M	528.1M
Operating Expenses
R&D Expense	114.8M	110.1M	110.7M	79.1M	74.2M
SG&A Expense	—	—	—	—	—
General & Admin Expense	367.1M	368.6M	361.2M	374.7M	297.5M
Selling & Marketing Expense	143.0M	139.2M	85.6M	86.2M	86.0M
Other Expenses	—	—	—	—	—
Total Operating Expenses	638.0M	628.9M	557.1M	536.2M	457.8M
Cost and Expenses	3.1B	3.2B	3.2B	3.1B	2.6B
Operating Income (EBIT)	74.8M	69.2M	43.0M	147.6M	130.0M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	69.9M	65.2M	40.0M	148.4M	127.8M
Income Tax Expense	14.2M	13.9M	22.1M	19.6M	13.9M
Bottom Line
Net Income	58.9M	53.9M	40.4M	106.2M	105.3M
Earnings from Cont. Ops	55.8M	51.3M	18.0M	128.8M	113.9M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	58.9M	53.9M	40.4M	106.2M	105.3M
Per Share
Basic EPS	CN¥0.09	CN¥0.09	CN¥0.07	CN¥0.21	CN¥0.21
Diluted EPS	CN¥0.09	CN¥0.09	CN¥0.07	CN¥0.21	CN¥0.21
Revenue Per Share	CN¥5.07	CN¥5.14	CN¥5.54	CN¥6.34	CN¥5.30
Shares
Basic Shares Outstanding	622.3M	621.9M	592.5M	504.0M	504.0M
Diluted Shares Outstanding	622.3M	621.9M	592.5M	504.0M	504.0M
Profitability Metrics
EBITDA	—	238.3M	205.9M	303.6M	258.6M
D&A	—	169.1M	162.9M	156.0M	128.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026